2-mercaptooctanoic acid | 90201-31-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-mercaptooctanoic acid
• 英文别名: Mercaptooctanoic acid；2-sulfanyloctanoic acid
• CAS: 90201-31-3
• 化学式: C₈H₁₆O₂S
• 分子量: 176.28
• InChiKey: WXVYGDSYOULXDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  38.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-mercaptooctanoic acid 在 乙醇 、 碘 作用下， 生成 2,5-dihexyl-3,4-dithia-adipic acid
  参考文献：
  名称：

  Eggerth, Journal of Experimental Medicine, 1931, vol. 53, p. 28

  摘要：

  DOI：
• 作为产物：
  描述：

  2-溴正辛酸 在 氨 作用下， 以 甲醇 、 水 、 乙腈 为溶剂， 反应 4.0h， 生成 2-mercaptooctanoic acid
  参考文献：
  名称：

  从5H-噻唑-4-酮和硝基烯烃催化合成对叔硫醇：双官能基于脲肽的布朗斯台德碱催化

  摘要：

  满载：基于脲肽的双官能布朗斯台德碱1有效促进α-巯基羧酸盐替代物与硝基烯烃的第一个直接催化迈克尔反应，该反应涉及完全取代的α-碳原子结构。

  DOI：

  10.1002/anie.201305644

文献信息

• Highly Stereoselective Synthesis of the Anti-Platelet Activating Factor, 4-Thiazolidinones, Using Silyl Derivatives of 2-Mercaptoalkanoic Acids
  作者：Yoo Tanabe、Hitomi Okumura、Masaki Nagaosa、Masanari Murakami

  DOI：10.1246/bcsj.68.1467

  日期：1995.5

  factor-active drugs. The use of the piperidine catalyst and no catalyst showed very high cis-stereoselectivity (cis/trans = 10/1—50/1) during the reaction. On the other hand, the trans-selective reaction was promoted by Ti(O-i-Bu)4 and Al(O-s-Bu)3 catalysts (cis/trans = 1/8—1/25). Both reactions were conducted with higher cis- and trans-selectivities as compared with those of the alkyl 2-mercaptoalkanoates under

  2-巯基链烷酸甲硅烷酯和芳基亚甲基胺的环缩合反应具有高立体选择性，可交替生成顺式和反式 2,5-二取代 4-噻唑烷酮，其中一些被称为抗血小板激活因子活性药物。使用哌啶催化剂和不使用催化剂在反应过程中表现出非常高的顺式立体选择性（顺式/反式=10/1—50/1）。另一方面，Ti(Oi-Bu)4和Al(Os-Bu)3催化剂促进了反式选择性反应（顺/反=1/8—1/25）。在温和条件下，与 2-巯基链烷酸烷基酯相比，这两种反应均以更高的顺式和反式选择性进行。使用三甲基甲硅烷基 2-(三甲基甲硅烷基硫基)丙酸酯和甲基 2-(三烷基甲硅烷基硫基)丙酸酯的环缩合反应在催化量 (0.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE TROUBLES NEUROMUSCULAIRES ET DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：KANDULA MAHESH

  公开号：WO2013017974A1

  公开（公告）日：2013-02-07

  The disclosures herein provide compounds of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceuiicai compositions may be formulated for peroral administration, transdermal administration, transmucosal, syrups, topical, extended release, sustained release, or injection. Such compositions may be used to treatment of metabolic condition, neuromuscular disorders and neurodegenerative diseases or its associated complications.

  本文提供的化合物公式1或其药学可接受的盐，以及其多晶形、对映体、立体异构体、溶剂化物和水合物。这些盐可以制成药物组成物。药物组成物可以制成口服、经皮、经黏膜、糖浆、局部、延迟释放、缓释或注射剂型。这些组成物可用于治疗代谢性疾病、神经肌肉疾病和神经退行性疾病或其相关并发症。
• Lipoic acid derivatives and their use in treatment of disease
  申请人：——

  公开号：US20020107234A1

  公开（公告）日：2002-08-08

  This invention relates to the identification of a novel class of therapeutic agents which selectively target and kill tumor cells and certain other types of diseased cells, and to compositions comprising lipoic acid derivatives which poison the pyruvate dehydrogenase complex specifically in such cells. This invention also provides for methods of using therapeutically effective amounts of the lipoic acid derivatives for the treatment of cancer and other diseases. The lipoic acid derivatives described herein have a wide range of preventive and therapeutic applications.

  本发明涉及一种新型治疗剂的鉴定，该治疗剂选择性地针对并杀死肿瘤细胞和某些其他类型的疾病细胞，并且涉及包含脂酰辅酶A衍生物的组合物，该衍生物特异性地破坏这些细胞中的丙酮酸脱氢酶复合物。本发明还提供了使用治疗有效量的脂酰辅酶A衍生物治疗癌症和其他疾病的方法。本发明中描述的脂酰辅酶A衍生物具有广泛的预防和治疗应用。
• MULTI-BRANCHED POLYALKYLENE GLYCOL POLYMER, METHOD FOR PRODUCING THE SAME, AND ADMIXTURE FOR CEMENT
  申请人：Sakamoto Noboru

  公开号：US20110160393A1

  公开（公告）日：2011-06-30

  The present invention provides a multi-branched polyalkylene glycol polymer useful for various applications, especially for an admixture for cement, a dispersant, admixture for cement, and cement composition each comprising the same, a thiol compound having a polyalkylene glycol chain useful for materials and the like of the polymer, and a method for easily and effectively producing the multi-branched polyalkylene glycol polymer and the thiol compound having a polyalkylene glycol chain at low cost. The multi-branched polymer comprises: a polyalkylene glycol chain; a residue of a compound having three or more active hydrogen atoms; and a polymer portion having a constitutional unit derived from a vinyl monomer component, one end of the polyalkylene glycol chain bonding to the residue, and a terminal oxygen atom of at least one of the other ends of the polyalkylene glycol chain bonding to a main chain end of the polymer portion directly or via an organic residue.

  本发明提供了一种多支链聚烷基醚聚合物，适用于各种应用，特别是水泥掺合剂、分散剂、水泥掺合剂和包含它们的水泥组合物，以及具有聚烷基醚链的巯基化合物，用于聚合物等材料，以及一种低成本、易于有效生产多支链聚烷基醚聚合物和具有聚烷基醚链的巯基化合物的方法。多支链聚合物包括：聚烷基醚链；具有三个或更多活性氢原子的化合物残基；以及具有从乙烯单体组分衍生的构成单元的聚合物部分，聚烷基醚链的一端与残基结合，聚烷基醚链的至少一个其他端的端氧原子直接或通过有机残基与聚合物部分的主链端结合。
• Guaiacol esters of alpha- and beta-mercaptopropionylalanine and alpha- and beta-mercaptopropionylglycine, process for their preparation and pharmaceutical compositions containing same
  申请人：Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP0013261A1

  公开（公告）日：1980-07-09

  Gualacol esters of alpha- and beta-mercaptopropionyl alanine and of alpha- and beta-mercaptopropionyl glycine having formulae: wherein R is hydrogen or methyl and Y is hydrogen or an acyl radical (acetyl, benzoyl or methoxycarbonyl). Pharmaceutical compositions containing these guaiacol esters have mucolytic activity. The process for manufacturing these guaiacol esters comprises preparing in a known per se manner a sulhydryl group-containing intermediate wherein the sulfhydryl is protected by a trityl or p-methoxybenzyl group, and removing the protective group under acid conditions.

  α-和β-巯基丙酰基丙氨酸以及α-和β-巯基丙酰基甘氨酸的愈创木酚酯，其化学式为 其中 R 是氢或甲基，Y 是氢或酰基（乙酰基、苯甲酰基或甲氧基羰基）。 含有这些愈创木酚酯的药物组合物具有粘液溶解活性。 制造这些愈创木酚酯的工艺包括以已知的本身方式制备含巯基的中间体，其中的巯基被三苯甲基或对甲氧基苄基保护，然后在酸性条件下去除保护基。